評論
打印
Profit margins for multinational pharmaceutical companies in China are being met with big pains on expiring patents and policy changes. President of the Pharmaceutical Association Committee Zhuo Yongqing said foreign and domestic pharma companies are experiencing slower growth. And while international companies once saw surging profits in years past, a slew of challenges have resulted in a turning of the tides.
因“專利到期”和政策調整，中國的跨國醫藥公司效益慘淡。藥品委員會主席卓永清認為，不管是外資公司還是國內醫藥公司，都出現了收益放緩現象。幾年前，國外醫藥公司一團紅火，但由于受到諸多挑戰，現已大不如前。
Drug giants Bristol-Myers Squibb and GlaxoSmithKline have each laid off some 1,000 employees in the past few years, attributing the moves to changes in their business model. Meanwhile, dismissed employees have said the layoffs were due to profit declines. In February, Merck ended a joint venture with its Chinese partner, cutting some 300 jobs in China.
過去幾年間，為了改變商業模式，藥業巨頭百時美施貴寶和葛蘭素史克均裁員約1千人。與此同時，解聘員工稱裁員是由于經濟效益下滑。今年2月，默克集團結束了與一家中國公司的合資計劃，裁減中國員工約300人。
Big Pharma has made large investments in China since 2010 to tap booming demand. But according to PharmAsia News, GSK reported a 3 percent decline in sales in China in the first quarter of this year. Eli Lilly and Co. reported 6 percent growth for first-quarter sales of this year, down 21 percent in 2014.
為了開發需求量，自2010年起，美國Big Pharma公司加大對中國投資力度。但根據“PharmAsia”新聞的報道，葛蘭素史克今年第一季度銷量減少了3%。美國禮來制藥今年第一季度只增長了6%，2014年下降了21%。
Around the world, drug makers are also coming up against a clock running out on patents for some of their best-selling drugs. Foreign drug makers in China have also long contended with lengthy approval processes to enter the market. For new drugs to enter the market, a senior executive at a drug company said it takes five to eight years for registration and then another two years for the drug to appear in state drug procurement catalogs.
在全球，許多醫藥公司還要面對暢銷藥物的“專利懸崖”問題。由于投入市場的審批流程過長，許多外國公司還要為此進行長期斗爭。為了讓新藥進入市場，一名公司高管稱，新藥注冊需要五到八年，進入國家醫保還需要兩年。
For Caixin Online, this is Diana Bates.
這是戴安娜·貝茨為您帶來的財新新聞報道。
譯文屬可可英語原創，未經允許，不得轉載。
